BioMarin gene therapy head splits for rival Vedere

Published: 25 June 2021

Vedere Bio II has announced gene therapy expert Gabor Veres as its new chief scientific officer. 

Massachusets-based Vedere is working on next generation gene therapies for vision loss caused by photoreceptor death – and now Veres has joined their mission. Previously vice president and head of gene therapy research at BioMarin, he has also served at Bluebird Bio and Applied Genetic Technologies.

The original Vedere Bio, founded by Cyrus Mozayeni, was bought for $150 million upfront by Novartis last year. Its successor, Vedere Bio II, is a new entity, but retains the same founders, management team, and employees.

"Gabor has over 15 years of experience leading preclinical research and development for international pharmaceutical and biotechnology companies and holds 20 years of experience in the development of cell and gene therapy products," said Mozayeni, chief executive officer and president of Vedere Bio II. "His extensive track record designing and executing gene therapy research programs for a range of diseases, including conditions of the eye, will be an incredible asset to our team as we continue our work to restore vision to patients with both genetic and non-genetic causes of vision loss."